High Growth Tech Stocks in the US Market

In This Article:

As the U.S. stock market experiences a positive streak, with the Dow Jones and S&P 500 extending their gains amidst strong earnings reports and potential tariff adjustments, investors are closely watching how these developments might impact various sectors, including technology. In this dynamic environment, identifying high growth tech stocks often involves looking for companies that demonstrate resilience in adapting to economic shifts and possess innovative capabilities that can leverage current market conditions effectively.

Top 10 High Growth Tech Companies In The United States

Name

Revenue Growth

Earnings Growth

Growth Rating

Super Micro Computer

20.27%

29.79%

★★★★★★

Alkami Technology

20.46%

85.16%

★★★★★★

Travere Therapeutics

28.65%

66.06%

★★★★★★

TG Therapeutics

26.06%

37.39%

★★★★★★

Arcutis Biotherapeutics

26.11%

58.46%

★★★★★★

Clene

62.08%

64.01%

★★★★★★

Alnylam Pharmaceuticals

23.08%

58.85%

★★★★★★

AVITA Medical

27.81%

55.17%

★★★★★★

Lumentum Holdings

21.34%

120.49%

★★★★★★

Ascendis Pharma

32.75%

59.64%

★★★★★★

Click here to see the full list of 233 stocks from our US High Growth Tech and AI Stocks screener.

We'll examine a selection from our screener results.

Halozyme Therapeutics

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Halozyme Therapeutics, Inc. is a biopharmaceutical company that focuses on the research, development, and commercialization of proprietary enzymes and devices both in the United States and internationally, with a market capitalization of approximately $7.47 billion.

Operations: Halozyme Therapeutics generates revenue primarily from the research, development, and commercialization of its proprietary enzymes, totaling approximately $1.02 billion. The company's focus is on leveraging its enzyme technology for various therapeutic applications across global markets.

Halozyme Therapeutics, a biotech firm, recently announced significant regulatory milestones with its ENHANZE® drug delivery technology. The European Medicines Agency's positive opinion for VYVGART®, developed using this technology, marks a pivotal advancement in treating chronic inflammatory conditions. Financially, Halozyme has shown robust performance with a 57.7% earnings growth over the past year, outpacing the industry's 40.6%. Moreover, their strategic share repurchases have reinforced shareholder value, with $250 million spent to buy back 3.29% of shares last quarter. This blend of innovative healthcare solutions and strong financial health underscores Halozyme's potential in high-growth biotechnology sectors.